Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Fei, Wang, Yao, Gao, Yongsheng, Meng, Xiangjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/
https://www.ncbi.nlm.nih.gov/pubmed/36110968
http://dx.doi.org/10.3389/fonc.2022.971192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468776/
https://www.ncbi.nlm.nih.gov/pubmed/36110968
http://dx.doi.org/10.3389/fonc.2022.971192

Ejemplares similares